Subscribe
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
VBCR Print Edition
We will request your mailing address on the next page.
VBCR E-Newsletters & Communications
I have reviewed and consent to the terms of
VBCR
's
Privacy Policy
, and
VBCR
has my permission to retain my information in its database, and to forward pertinent communications to me.
Home
Categories
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Media Library
CE
News
In The News
FDA Updates
Drug Updates
News Feed
Resources
Supplements
Conference Highlights
Author Guidelines
About Us
About Us
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Saturday, 20 October 2018
Authored Items
Hypermobility Syndrome Underrecognized, Requires Team-Based Management
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5
in
Rheumatic Diseases
Neuropathies in Rheumatic Diseases Encompass Wide Spectrum of Diagnoses
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5
in
Rheumatic Diseases
Patients with Rheumatoid Arthritis Cite Improvements in Pain, Quality of Life as Treatment Goals
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5
in
Rheumatoid Arthritis
Celecoxib Demonstrates Better Results than Acetaminophen in Patients with Low Back Pain
Wayne Kuznar
VBCR - August 2016, Vol 5, No 4
in
Back Pain
Entrectinib Shows Strong Activity Against a Range of Rare Solid Tumors with Molecular Abnormalities
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5
in
Emerging Therapies
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5
in
Emerging Therapies
Updated NCCN Guideline Calls for EGFR Mutations Testing in All Patients with NSCLC
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5
in
Lung Cancer
Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5
in
Breast Cancer
Nivolumab Monotherapy Prolongs Survival in Patients with Advanced Melanoma
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5
in
Melanoma
NCCN Panel Examines Impact of the Presidential Election on Cancer Care
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4
in
NCCN Conference Highlights
Vice President Biden Promises to Remove Political Barriers to Research, Calls for Cooperation
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4
in
AACR Meeting Highlights
Updated NCCN Multiple Myeloma Guideline Expands Patient Eligibility and Therapeutic Options
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4
in
NCCN Conference Highlights
Immunotherapy Takes Center Stage in the Updated NCCN Guideline for Advanced Melanoma
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4
in
NCCN Conference Highlights
NCCN Evidence Blocks Help Frame Value-Based Decisions for Systemic Therapies
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4
in
NCCN Conference Highlights
Pembrolizumab Elicits High Response in Merkel-Cell Carcinoma
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4
in
AACR Meeting Highlights
Medical Costs, Lost Productivity Are Substantial for Chronic Migraine
Wayne Kuznar
VBCN - April 2016 Volume 3, No 1
in
Migraine
CSF Biomarkers and Amyloid PET Equally Accurate in Identifying Early-Stage Alzheimer’s Disease
Wayne Kuznar
VBCN - April 2016 Volume 3, No 1
in
Alzheimer’s Disease/Dementia
Call to Action: Epilepsy-Related Mortality Should Become a Public Health Priority
Wayne Kuznar
VBCN - April 2016 Volume 3, No 1
in
Epilepsy Update
Uncovering Molecular Genetic Basis in Multiplex Families with Epilepsy
Wayne Kuznar
VBCN - April 2016 Volume 3, No 1
in
Epilepsy Update
Oncology Medical Home Shows Significant Cost-Savings, Improved Care Delivery
Wayne Kuznar
VBCC - December 2015, Vol 6, No 11
in
AVBCC 2015 5th Annual Conference
Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers
Wayne Kuznar
VBCC - December 2015, Vol 6, No 11
in
Personalized Medicine
Getting to Value-Based Cancer Care in the ’Omics Era Requires Data Integration
Wayne Kuznar
VBCC - December 2015, Vol 6, No 11
in
AVBCC 2015 5th Annual Conference
Nursing Certification Through Portfolio Promotes Professional Development and Performance
Wayne Kuznar
VBCR - December 2015, Volume 4, No 6
in
Online First
,
The Rheumatology Nurse
NCCN Incorporates Affordability Criteria in Its Clinical Guidelines to Assess Value of Cancer Therapies
Wayne Kuznar
VBCC - November 2015, Vol 6, No 10
in
NCCN Conference Highlights
Next-Generation Sequencing Propelling Forward Cancer Knowledge, Therapy
Wayne Kuznar
VBCC - November 2015, Vol 6, No 10
in
AVBCC 2015 5th Annual Conference
Understanding the Role and Impact of Biosimilars in Rheumatology
Wayne Kuznar
VBCR - October 2015, Volume 4, No 5
in
RNS Conference News
FDA Issues Draft Guidance on Naming of Biosimilars
Wayne Kuznar
VBCR - October 2015, Volume 4, No 5
in
FDA News & Updates
Pain Management in Pediatric Patients: Focus on Function
Wayne Kuznar
VBCR - October 2015, Volume 4, No 5
in
RNS Conference News
Assess Vaccine Status at Initial Patient Visit
Wayne Kuznar
VBCR - October 2015, Volume 4, No 5
in
RNS Conference News
An Accountable Payment Model a “Win-Win-Win” Solution to Value-Based Care
Wayne Kuznar
VBCC - October 2015, Vol 6, No 9
in
AVBCC 2015 5th Annual Conference
Value Proposition of Oncology Pharmaceuticals: Drug Manufacturers Increasing Focus on Patient Support
Wayne Kuznar
VBCC - October 2015, Vol 6, No 9
in
AVBCC 2015 5th Annual Conference Abstracts
Enzalutamide Outperforms Bicalutamide in 2 Trials of Prostate Cancer
Wayne Kuznar
VBCC - September 2015, Vol 6, No 8
in
Prostate Cancer
Oncology Pipeline Full, and Not Just with Immunotherapies
Wayne Kuznar
VBCC - September 2015, Vol 6, No 8
in
Emerging Therapies
Oncology Specialty Pharmacy Promotes the Coordination of Care
Wayne Kuznar
VBCC - September 2015, Vol 6, No 8
in
AVBCC 2015 5th Annual Conference
Oncology Medical Home Accreditation by Community Oncology Alliance Making Progress
Wayne Kuznar
VBCC - September 2015, Vol 6, No 8
in
AVBCC 2015 5th Annual Conference
Cancer Drugs Continue to Drive Pharmaceutical Spending Trends
Wayne Kuznar
VBCC - August 2015, Vol 6, No 7
in
AVBCC 2015 5th Annual Conference
Care Pathway for NSCLC Cuts Chemotherapy Cost
Wayne Kuznar
VBCC - August 2015, Vol 6, No 7
in
Economics of Cancer Care
Cell Surface Amino Acid Potential as Prostate Cancer Biomarker
Wayne Kuznar
VBCC - August 2015, Vol 6, No 7
in
Personalized Medicine
High-Value Narrow Networks and Patient Safety Organizations the Future of Cancer Care
Wayne Kuznar
VBCC - August 2015, Vol 6, No 7
in
AVBCC 2015 5th Annual Conference
Personalized Medicine Affordability Lies in Enhanced Predictors of Response to Therapy
Wayne Kuznar
VBCC - August 2015, Vol 6, No 7
in
AVBCC 2015 5th Annual Conference
The Push Toward Value-Based Payment for Oncology
Wayne Kuznar
VBCC - July 2015, Vol 6, No 6
in
Value in Oncology
Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
VBCC - July 2015, Vol 6, No 6
in
ASCO 2015 Highlights
Expert Panel Discusses Quality Measures, Data Collection, and Outcomes in Oncology
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5
in
AVBCC 2015 5th Annual Conference
Risk Management a Key Challenge in the New Oncology Payment Models
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5
in
AVBCC 2015 5th Annual Conference
Comprehensive Genomic Profiling Enables Efficient “N of 1” Trials
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5
in
AVBCC 2015 5th Annual Conference
Pathways Reduce Care Variation and Cost of Care, Improve Overall Outcomes
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5
in
AVBCC 2015 5th Annual Conference
“Data in Motion” Will Promote Patient-Centric Care Models
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5
in
AVBCC 2015 5th Annual Conference
Immunotherapy Makes Headwinds into Liver Cancer
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5
in
ASCO 2015 Highlights
AVBCC 5th Conference: Continuing Challenges for Optimizing Value in Oncology
Wayne Kuznar
VBCC - May 2015, Vol 6, No 4
in
AVBCC 2015 5th Annual Conference
Promising Therapies in Multiple Drug Classes Being Explored for B-Cell Lymphomas
Wayne Kuznar
VBCC - May 2015, Vol 6, No 4
in
NCCN 2015 Updates
Many Targeted Drugs in Development for Multiple Myeloma: Monoclonal Antibodies Close to Approval
Wayne Kuznar
VBCC - May 2015, Vol 6, No 4
in
NCCN 2015 Updates
In CML, Assess Response to First-Line TKI at 3 Months
Wayne Kuznar
VBCC - May 2015, Vol 6, No 4
in
NCCN 2015 Updates
Pathways Have the Potential to Deliver Personalized Medicine
Wayne Kuznar
VBCC - May 2015, Vol 6, No 4
in
AVBCC 2015 5th Annual Conference
NCCN Panel Addresses Value-Based Care in Oncology
Wayne Kuznar
VBCC - April 2015, Vol 6, No 3
in
Economics of Cancer Care
Treatment for CLL Will Incorporate More Targeted Therapies in the Near Future
Wayne Kuznar
VBCC - April 2015, Vol 6, No 3
in
NCCN Conference Highlights
NCCN Issues New Smoking-Cessation Guidelines for Patients with Cancer
Wayne Kuznar
VBCC - April 2015, Vol 6, No 3
in
NCCN Conference Highlights
Immune Checkpoint Blockade Shows Durable Responses in Lung and Kidney Cancers, Metastatic Melanoma
Wayne Kuznar
VBCC - April 2015, Vol 6, No 3
in
NCCN Conference Highlights
Updated NCCN Guideline for Prostate Cancer Allows Early Treatment with Docetaxel
Wayne Kuznar
VBCC - April 2015, Vol 6, No 3
in
NCCN Conference Highlights
Value of New Drugs for Hematologic Cancers—Improving Quality, Extending Survival
Wayne Kuznar
VBCC - March 2015, Vol 6, No 2
in
Economics of Cancer Care
Blinatumomab Immunotherapy Attacks Minimal Residual Disease in ALL, Leads to High Rates of Complete Response
Wayne Kuznar
VBCC - March 2015, Vol 6, No 2
in
Leukemia
Vosaroxin, a Quinolone Derivative, Extends Survival in Older Patients with Acute Myeloid Leukemia
Wayne Kuznar
VBCC - March 2015, Vol 6, No 2
in
Leukemia
Monitoring Response to TKI Therapy by PCR Improves Outcomes in Chronic Myeloid Leukemia
Wayne Kuznar
VBCC - March 2015, Vol 6, No 2
in
Leukemia
Immunotherapy with PD-1 Inhibitors the Newest Breakthrough in Hodgkin Lymphoma
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights
in
Lymphoma
The Hematology Pipeline Is Abundant
Kate Smith
,
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights
in
Emerging Therapies
Once Off Patent, Imatinib Will Be the Most Cost-Effective Treatment for Newly Diagnosed CML
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights
in
Health Economics
Orphan Drug Expenditures in the United States Expected to Stabilize
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights
in
Health Economics
Pracinostat-Azacitidine Combination Generates Responses in Older Adults with Acute Myeloid Leukemia
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights
in
Leukemia
Sorafenib Prolongs Event- and Relapse-Free Survival in Acute Myeloid Leukemia
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights
in
Leukemia
CAR-T Achieves High Rate of Remission in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights
in
Leukemia
Immunotherapy’s Future May Be in Combinations
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1
in
GI Cancers Symposium
More Evidence that Low Vitamin D Levels Reduce Survival in Metastatic Colorectal Cancer
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1
in
GI Cancers Symposium
PD-L1 Inhibitor Pembrolizumab Produces Good Responses in Advanced Gastric Cancer
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1
in
GI Cancers Symposium
FOLFOXIRI Regimen a New Upfront Option for Some Patients with Metastatic Colorectal Cancer
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1
in
GI Cancers Symposium
Use of Advanced Practice Providers May Accrue Cost-Savings in Stem-Cell Transplant
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1
in
Economics of Cancer Care
Multiple Myeloma No Longer Considered a Single Disease Entity, as Reflected by New Treatment Regimens
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1
in
ASH 2014 Highlights
First-Line Therapy Failure in Patients with MDS Incurs High Financial Burden
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1
in
ASH 2014 Highlights
Genomic Landscape of Pancreatic Cancer Being Uncovered, Showing 4 Common Mutations, with KRAS Almost Ubiquitous
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1
in
Personalized Medicine
Immunotherapy the Newest Breakthrough in Hodgkin Lymphoma
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10
in
ASH 2014 Highlights
Diagnostic Tests Will Face Value-Based Pricing Under Payment Reform
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10
in
AVBCC 2014 4th Annual Conference
Providing Financial Incentives for Patients with Cancer to Participate in Their Care Improves Efficiency
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10
in
AVBCC 2014 4th Annual Conference
Medical Stop-Loss Insurance About to Get Riskier as Oncology Drug Pipeline Gets Pricier
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10
in
AVBCC 2014 4th Annual Conference
Cancer Drug Pricing in the United States: What Is Driving the High Costs?
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10
in
ASH 2014 Highlights
Payers Debate the Economics of Personalized Medicine in Oncology
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10
in
Economics of Cancer Care
Genetic Profiling Can Identify “Actionable” Mutations in Tumors That Are Missed by Traditional Tests
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10
in
Personalized Medicine
New Approaches to Treatment in the Era of Molecular Biomarkers
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10
in
Personalized Medicine
New Oncology Models Emerging with Shift from Volume-Based to Value-Based Reimbursement
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10
in
AVBCC 2014 4th Annual Conference
Pathways-Based Cancer Care Reduces Hospitalizations, Care Variation, and Costs
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10
in
AVBCC 2014 4th Annual Conference
Personalized Medicine in Oncology: NICE Grappling with Assigning Value to New Diagnostics and Medical Technologies
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9
in
Personalized Medicine
Individualizing Dosing of 5-FU with Pharmacokinetic Test Is Cost-Effective
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9
in
Economics of Cancer Care
Routine Imaging Costly in B-Cell Lymphoma, Rarely Picks Up Relapse After Remission
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9
in
Economics of Cancer Care
Adoption of Private Health Exchanges by Employers Expected to Grow Rapidly
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9
in
AVBCC 2014 4th Annual Conference
The Changing Healthcare Payment, Regulation, and Delivery Environments
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9
in
AVBCC 2014 4th Annual Conference
Cost Levers Increasingly Being Incorporated into Health Benefit Designs
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9
in
AVBCC 2014 4th Annual Conference
Employers Are Now Viewing Healthcare as an Investment Rather than an Expense
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9
in
AVBCC 2014 4th Annual Conference
Shifts to Value-Based Care and Payment Models Are Improving Quality of Care
Wayne Kuznar
VBCR - October 2014, Volume 3, No 5
in
Health Economics
HER2-Derived Vaccine Cuts Recurrences in Patients with High-Risk Breast Cancer
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8
in
Breast Cancer
Adding Luteinizing Hormone-Releasing Hormone Agonist to Chemotherapy Preserves Fertility in Women with Breast Cancer
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8
in
Breast Cancer
Does Comparative Effectiveness Research Have Value in Oncology?
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8
in
AVBCC 2014 4th Annual Conference
Oncology Medical Home Pilot Improves Outcomes
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8
in
AVBCC 2014 4th Annual Conference
Managing Cancer at the Workplace Enhances Productivity, Has Value for Employers
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8
in
AVBCC 2014 4th Annual Conference
Cancer Support Community: Empowering Patients through Knowledge and Psychosocial Care
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8
in
AVBCC 2014 4th Annual Conference
Patient-Centered Oncology Medical Home Improves Health Outcomes at Lower Costs to Patients and Payers
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8
in
AVBCC 2014 4th Annual Conference
Maximizing Value and Quality in Gynecologic Cancer Care—Work in Progress
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7
in
Value in Oncology
Predictive Testing Holds More Value to Oncology Stakeholders than Prognostic Testing
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7
in
AVBCC 2014 4th Annual Conference
Improving the Value Paradigm in Drug Development Will Require More Efficient Clinical Trials, New Biomarkers
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7
in
AVBCC 2014 4th Annual Conference
Payer Challenges in Oncology: Establishing Standards and Access to Quality Care
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7
in
AVBCC 2014 4th Annual Conference
Comparative Effectiveness Research Helps Define Value in Cancer Care
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7
in
AVBCC 2014 4th Annual Conference
Oncologists Can Become Value-Based Providers Using Evidence to Guide Patient Care
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7
in
Value in Oncology
Next-Generation Sequencing Provides Value to Multiple Stakeholders
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7
in
AVBCC 2014 4th Annual Conference
Should You Consider the Interests of Society at Large When Treating the Individual Patient?
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7
in
Value in Oncology
Shifts to Value-Based Care and Payment Models Are Improving Quality of Care
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
Reimbursement
Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
Breast Cancer
Upfront Docetaxel Markedly Improves Survival
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
Prostate Cancer
Oncology Pipeline Bustling, But Value Concerns Lead to Increased Payer Scrutiny
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
AVBCC 2014 4th Annual Conference
Using IBM Watson Electronic System to Guide Patient Management in Oncology
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
AVBCC 2014 4th Annual Conference
Big Data and CancerLinQ Can Help to Optimize Patient Outcomes in Oncology
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
AVBCC 2014 4th Annual Conference
QOPI Measures Identify Areas for Quality Improvement in Oncology Practice
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
AVBCC 2014 4th Annual Conference
Necitumumab Extends Survival of Patients with Squamous Lung Cancer
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
Lung Cancer
Patients with Cancer Are Not Asking for Low-Value Tests or Therapies
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
Economics of Cancer Care
Most Hospital Readmissions Not Preventable for Patients with Cancer
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
Economics of Cancer Care
Even When Adjusting for Improved Survival, Newer Anticancer Drugs Are More Expensive than Older Ones
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
Economics of Cancer Care
2014 Oncology Pipeline Looks Impressive
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
Emerging Therapies
Patients with Cancer Need Psychosocial Support, Expression of Caring
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6
in
AVBCC 2014 4th Annual Conference
Neurologists Must Maintain Patient-Centered Care Even When Facing Economic Pressures
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Health Economics
Fourfold Variability Found in Hospital Charges for Stroke Diagnostic Tests
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Stroke
Earlier Use of Adjunctive Antiepileptic Drugs in Patients with Refractory Disease Could Reduce Costs
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Health Economics
Is No Evidence of Disease Activity an Achievable Goal in Patients with RRMS?
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Multiple Sclerosis
Medical Marijuana Helpful for Some MS Symptoms
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Multiple Sclerosis
Extended Natalizumab Dosing May Reduce PML Risk in Patients with Multiple Sclerosis
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Multiple Sclerosis
Knowledge of Antiepileptic Drug Formulations Key to Accurate Prescribing
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Epilepsy Management
Breakthrough Seizures in Treatment-Adherent Patients Are Costly
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Epilepsy Management
Precision Medicine in the Treatment of Epilepsy
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Personalized Medicine in Neurology
Using Genomics in Clinical Practice in Neurology
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Personalized Medicine in Neurology
Novel Protocol Improves Cognition, Outperforms Community Treatment of Dementia
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Alzheimer’s Disease/Dementia
Two Monoclonal Antibodies Hold Promise of Migraine Prevention
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Migraine
Breath-Powered Intranasal Sumatriptan Has Rapid Absorption, Provides Fast Migraine Relief
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2
in
Migraine
Significant Hurdles Must Be Overcome to Actualize the Value of Personalized Medicine
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5
in
AVBCC 2014 4th Annual Conference
The Value of Personalized Medicine Lies in Evidence Thresholds, Drug Testing, and Pricing Trends
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5
in
AVBCC 2014 4th Annual Conference
Worksite Health Centers Can Help Employees Manage Cancer
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5
in
AVBCC 2014 4th Annual Conference
Worksite Pharmacies Can Enhance Overall Drug Management of Patients with Cancer
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5
in
AVBCC 2014 4th Annual Conference
Patients with Cancer Want but Are Not Getting Information on the Cost of Their Therapy
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5
in
ASCO 2014 Highlights
Delaying ADT for PSA-Only Relapse May Be Viable Option for Men with Prostate Cancer and PSA-Only Relapses
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5
in
ASCO 2014 Highlights
AVBCC Expert Panel: Impact of Personalized Medicine on Future and Current Therapies
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5
in
AVBCC 2014 4th Annual Conference
Emerging Targeted Therapies for Advanced Pancreatic Cancer Show Promise
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4
in
Pancreatic Cancer
Updated NCCN Survivorship Guidelines
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4
in
Survivorship
Advances in the Treatment of Patients with Castration-Resistant Prostate Cancer
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4
in
Prostate Cancer
Treatment Paradigm for Lung Cancer Shifting Toward Targeted Therapies, Immunotherapy
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4
in
Lung Cancer
AVBCC Fourth Conference: Optimizing Value and Stakeholder Integration in Cancer Care
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4
in
AVBCC 2014 4th Annual Conference
Payers Facing Multiple Challenges in Ensuring Access to Cancer Care
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4
in
AVBCC 2014 4th Annual Conference
Implications of the ACA for Cancer Care
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3
in
Economics of Cancer Care
Ramucirumab Improves Survival as Second-Line Therapy in Patients with Advanced Gastric Cancer
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3
in
Gastric Cancer
New Molecular Test to Monitor Breast Cancer Recurrence by Sequencing Circulating Tumor Cells
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3
in
Personalized Medicine
Personalized Cancer Care: Combination Therapies May Be Key to Hitting Tumor Heterogeneity
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3
in
Personalized Medicine
In the Real World, Bevacizumab Improves Survival in Patients with Metastatic Colorectal Cancer
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3
in
Colorectal Cancer
Updated NCCN Guidelines for Non-Hodgkin Lymphoma Note Controversy Related to B-Cell Disease Management
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3
in
NCCN 2014 Conference
Updated NCCN Melanoma Guideline Adds BRAF Inhibitor and MEK Inhibitor to First-Line Targeted Therapeutic Options
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3
in
NCCN 2014 Conference
New Pathways, Targeted Therapies Being Explored in Hepatocellular Carcinoma
Wayne Kuznar
VBCC - March 2014, Volume 5, No 2
in
Pathways
Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money
Wayne Kuznar
VBCC - March 2014, Volume 5, No 2
in
Economics of Cancer Care
Understanding Molecular Subtypes Is Basis for Genomic Medicine in Prostate Cancer
Wayne Kuznar
VBCC - March 2014, Volume 5, No 2
in
Personalized Medicine
Biomarker Development and Validation Crucial to Appropriate Use of Emerging Treatments in Oncology
Wayne Kuznar
VBCC - March 2014, Volume 5, No 2
in
Personalized Medicine
Immunotherapy Holds Promise to Extend Survival in GI Cancers
Wayne Kuznar
VBCC - March 2014, Volume 5, No 2
in
Immunotherapy
Hematologic Drug Pipeline Boasts Novel Approaches
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1
in
Emerging Therapies
Decitabine More Cost-Effective than Conventional Induction in Older Patients with AML
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1
in
Economics of Cancer Care
Physicians Must Consider the Financial Burden Associated with Allogeneic Transplants
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1
in
Economics of Cancer Care
Rituximab Infusions Costlier When Given in the Hospital than in the Office Setting
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1
in
Economics of Cancer Care
Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1
in
Economics of Cancer Care
Peripheral T-Cell Lymphoma Associated with High Clinical Burden, Resource Utilization, and Costs
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1
in
Economics of Cancer Care
Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1
in
Personalized Medicine
Adjuvant Chemotherapy Benefit in Stage II Colon Cancers Is Small, May Even Cause Harm, Depending on Prognostic Markers
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1
in
GI Cancers Symposium
Rheumatology Nursing Is Evolving Rapidly, Prominent Role Already Assumed
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1
in
The Rheumatology Nurse
Investigational Anti–IL-6 Monoclonal Antibody Shows Promising Response Rates in RA
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1
in
Rheumatoid Arthritis
Biologics May Not Be the Cost Savers They Are Assumed to Be in RA
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1
in
Health Economics
Step-Therapy Drug Policies Rarely Limit Utilization of High-Cost Specialty Pharmaceuticals
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1
in
Health Economics
JAK Inhibitors and Other Biologics Are the Future of RA Treatment
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1
in
Rheumatoid Arthritis
Investigational IL-17 Inhibitor Induces Clinical Response in Patients with Psoriatic Arthritis
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1
in
Psoriatic Arthritis
National Survey Results: Rheumatologists Not Treating Patients with Gout Aggressively Enough
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1
in
Gout
In Systemic Lupus Erythematosus, Glucocorticoid Dose Linked to Adverse Events and Overall Costs
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1
in
Lupus
Consideration of Pathogenesis Leads to Appropriate Therapy in Patients with Severe Thrombocytopenia and Lupus
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1
in
Lupus
The Top 5 Things You May Have Missed at SABCS
Wayne Kuznar
VBCC - Meeting Highlights
in
SABCS 2013
Triple-Negative Breast Cancer Continues to Confound, New Approaches Being Explored
Wayne Kuznar
VBCC - Meeting Highlights
in
SABCS 2013
Effective End-of-Life Care Means Symptom Management, Preserving Quality of Life
Wayne Kuznar
VBCC - Meeting Highlights
in
SABCS 2013
Reexamination of Evidence Supports Routine Mammography to Prevent Breast Cancer Death
Wayne Kuznar
VBCC - Meeting Highlights
in
SABCS 2013
Practical Problems Must Be Overcome to Move Personalized Medicine Forward in Oncology
Wayne Kuznar
VBCC - November 2013, Volume 4, No 9
in
Personalized Medicine
Next-Generation Sequencing Identifies “Actionable” Genomic Alterations in Solid Tumors
Wayne Kuznar
VBCC - November 2013, Volume 4, No 9
in
Personalized Medicine
Bronchial/Nasal Gene-Expression Tests for Early Detection of Lung Cancer
Wayne Kuznar
VBCC - November 2013, Volume 4, No 9
in
Personalized Medicine
Redesigning Clinical Trials Necessary to Enhance Discovery of Effective Targeted Drugs in the Genomic Era
Wayne Kuznar
VBCC - October 2013, Volume 4, No 8
in
Personalized Medicine
Emerging Therapies and New Approaches in the “Double-Refractory” Setting in Myeloma
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7
in
Drug Update
New Technologies Bring No Upward Shift in Treatment of Local Prostate Cancer
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7
in
Prostate Cancer
Chemotherapy-Induced Neuropathy Can Persist a Decade after Stopping Treatment for Colorectal Cancer
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7
in
Drug Update
Mammography Screening Rates Enhanced by Copay Elimination
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7
in
Economics of Cancer Care
Poor Adherence to Oral Cancer Drugs a Growing Concern
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7
in
Economics of Cancer Care
Causes for Hospital Readmissions of Patients with Cancer
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7
in
Economics of Cancer Care
ASCO President Highlights Bridges to Conquer Cancer
Wayne Kuznar
VBCC - July 2013, Volume 4, No 6
in
Economics of Cancer Care
Variations in Cancer Treatment Raise Average Cost of Care by $25,000 per Patient
Wayne Kuznar
VBCC - June 2013, Volume 4, No 5
in
ASCO Annual Meeting
Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer
Wayne Kuznar
VBCC - June 2013, Volume 4, No 5
in
ASCO Annual Meeting
Use of High-Cost Tests for Lung Cancer Surveillance Rising
Wayne Kuznar
VBCC - June 2013, Volume 4, No 5
in
Economics of Cancer Care
Update on Initial Therapy of Multiple Myeloma and Emerging Agents for the Refractory Setting
Wayne Kuznar
VBCM - Meeting Highlights
in
ASCO 2013
Variations in Cancer Treatment Raise Average Cost of Care by $25,000 Per Patient
Wayne Kuznar
VBCC - News
Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer
Wayne Kuznar
VBCC - News
Personalized Immunotherapy plus Sunitinib Doubles Survival in Advanced Kidney Cancer
Wayne Kuznar
VBCC - March 2013, Volume 4, No 3
in
Personalized Medicine
Ruxolitinib Treatment Reduces Myelofibrosis Symptoms, Spleen Size
Wayne Kuznar
VBCC - February 2013, Volume 4, No 2
in
ASH Annual Meeting
Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia
Wayne Kuznar
VBCC - January 2013, Volume 4, No 1
in
ASH Annual Meeting
Unforeseen Hospital Admissions Are Frequent for Patients Receiving Radiotherapy
Wayne Kuznar
VBCC - July 2012, Volume 3, No 5
in
ASCO Annual Meeting
Cancer Screening Saves Lives, Is Cost-Effective
Wayne Kuznar
VBCC - July 2012, Volume 3, No 5
in
ASCO Annual Meeting
Tivozanib Outperforms Sorafenib as First-Line Treatment in Advanced Renal-Cell Carcinoma
Wayne Kuznar
VBCC - July 2012, Volume 3, No 5
in
ASCO Annual Meeting
Quality of Life Drives Patient Preference for Metastatic Renal-Cell Carcinoma Drug
Wayne Kuznar
VBCC - July 2012, Volume 3, No 5
in
ASCO Annual Meeting
In Head-to-Head Comparison, Continuous Beats Intermittent Hormonal Therapy for Metastatic Prostate Cancer
Wayne Kuznar
VBCC - June 2012, Volume 3, No 4
in
ASCO Annual Meeting
Personalized Vaccine Promising When Added to Sunitinib in Patients with Metastatic Renal-Cell Carcinoma
Wayne Kuznar
VBCC - March 2012, Volume 3, No 2
in
Genitourinary Cancers Symposium
Dose Escalation of Axitinib as Second-Line Treatment of mRCC May Be Needed to Optimize Outcome
Wayne Kuznar
VBCC - March 2012, Volume 3, No 2
in
Genitourinary Cancers Symposium
Many Patients with mRCC Ineligible for Clinical Trials
Wayne Kuznar
VBCC - March 2012, Volume 3, No 2
in
Genitourinary Cancers Symposium
External Beam Radiation More Toxic, Costlier than Brachytherapy or Prostatectomy
Wayne Kuznar
VBCC - March 2012, Volume 3, No 2
in
Genitourinary Cancers Symposium
Understanding the 340B Drug Pricing Program Requirements
Wayne Kuznar
VBCC - Other
Comparative Effectiveness Analysis of 3 Radiation Therapies for Prostate Cancer
Wayne Kuznar
VBCC - February 2012, Volume 3, No 1
in
Genitourinary Cancers Symposium
High Out-of-Pocket Costs Degrade Quality of Cancer Care
Wayne Kuznar
VBCC - News
Value-Based Insurance Design in Oncology
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Value in Oncology
Payer Trends in Oncology: Challenges and Solutions
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
AVBCC Annual Conference
The Role of Molecular Diagnostics in Cancer Treatment
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Cancer Care
Benefit Design Trends in Oncology Management
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Oncology Benefit Edition
NCCN Guidelines Inform Decisions Across the Continuum of Cancer Care
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
NCCN Guidelines
The Age of Personalized Oncology Therapies
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Personalized Medicine
A New Option for Metastatic Breast Cancer
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Breast Cancer
Community Oncology Clinics under Increasing Financial Pressure
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Community Oncology
Oncologists Face Economic Challenges while Improving Patient Care
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Practice Management
Patient Navigation and Patient Assistance Programs in Oncology
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Patient Navigation
Oncology Drug Reimbursement and Administration Benchmarks
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Reimbursement
Oncology Pharmacy as a Specialty
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Oncology
Medical and Pharmacy Directors’ Strategies to Improve Cancer Care Management
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Cancer Care
The Impact of Therapy Type on Clinical Fragmentation in Oncology Care
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4
in
Oncology
Hospital Implements New Oral Chemotherapy Handling Process in Effort to Increase Safety
Wayne Kuznar
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
For Overweight Patients, Dosing Chemotherapy Based on Total Body Weight Does Not Lead to More Toxicities
Wayne Kuznar
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
Cost-Effectiveness Comparison: FOLFIRI versus FOLFOX
Wayne Kuznar
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
Preventing Emesis Can Save Money
Wayne Kuznar
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
Economic Analysis of Chemo-Induced Nausea and Vomiting
Wayne Kuznar
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
Last modified: March 29, 2012
Home
Categories
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Media Library
CE
News
In The News
FDA Updates
Drug Updates
News Feed
Resources
Supplements
Conference Highlights
Author Guidelines
About Us
About Us
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
